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Available treatments for severe (class III, IV, and V) lupus
nephritis (LN) have expanded greatly over the last 40 years.
In the 1970s and 1980s, cyclphosphamide (CYC), in
combination with glucocorticoids, gained favor as induction
and maintenance therapy for severe LN. However, the
adverse event profile of CYC led to the search for other
medications for severe LN. Beginning in the late 1990s,
mycophenolate mofetil (MMF) was introduced as induction
and maintenance therapy for severe LN. This review
discusses the clinical trial results, pharmacology, cost-
effectiveness, and adverse effect profiles of CYC compared to
MMF for induction and maintenance therapy for severe LN.
The authors conclude that MMF should be considered
first-line induction and maintenance treatment therapy
for severe LN, although CYC may have a place under
specific clinical and economic circumstances.
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Efficacy of cyclophosphamide (CYC) versus mycophenolate
mofetil (MMF) in the treatments of severe lupus nephritis (LN)
An improvement in renal and patient survival for adults and
children with severe (class III/focal proliferative, class IV/
diffuse proliferative, and class V/membranous) LN has
occurred over the past four decades with the introduction
of new treatment options.1,2 During the 1970s, the results of
small clinical trials prompted physicians to add cytotoxic
agents to standard glucocorticoid therapy in the treatment of
severe LN. Modern therapy for severe LN was ushered in
during the 1980s and 1990s, with reports from the National
Institutes of Health (NIH), which concluded that chronic
treatment regimens containing intravenous (i.v.) CYC and
steroids were superior to steroids alone in preserving kidney
function.3,4 These differences in renal function were not
evident until at least 5 years of treatment, and long-term
follow-up data were only available for a few patients.
Nevertheless, the conclusion that i.v. CYC was a superior
treatment in severe LN led to many more trials as we entered
the new millennium.
In 2002, the Euro-Lupus Nephritis Trial (ELNT) showed
equivalent efficacy and less side effects in a European cohort
using an attenuated regimen of i.v. CYC (using six biweekly
fixed intravenous doses of 500mg i.v. CYC) compared with
the NIH regimen (0.5–1 g/m2 monthly for 6 months, followed
by repeat dosing every 3 months).5 The efficacy of this
regimen was confirmed in a subsequent 10-year follow-up
study.6 The ELNT regimen reduced the average total
induction dose of i.v. CYC from 8.5 to 3.0 g. Despite the
decreased side-effect profile of this ELNT regimen (although
not statistically significant), the adverse events associated
with i.v. CYC were still notable (including severe infections,
bone marrow suppression, gonadal toxicity, hemorrhagic
cystitis, and the risk of malignancy). Although outcomes
were improving, these adverse events combined with the
continued morbidity and mortality associated with severe LN
necessitated the advent of alternate therapies.
MMF was introduced into use in renal transplant patients
in the 1990s and was shown to have a favorable safety profile.
Preclinical animal studies then demonstrated that MMF was
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effective as induction treatment in severe LN.7,8 Several
randomized clinical studies have since followed in humans
(Table 1). The largest trials demonstrated that MMF was
equivalent, and possibly superior, to i.v. CYC as induction
therapy for severe LN, with a safer side-effect profile.9,10
Ginzler et al.10 randomized 140 patients with severe LN and
an average serum creatinine of 1.1mg/dl to receive oral MMF
(mean dose 2.7 gm/d) or NIH-dose i.v. CYC as induction
therapy for 24 weeks. In this open-label and multicenter trial,
39 patients (23%) did not complete the full treatment course.
A significantly higher percentage of patients in the MMF
group reached the primary end point (complete remission)
compared with i.v. CYC at 24 weeks, and more pyogenic
infections and hospitalizations occurred in the i.v. CYC
group. Appel et al.9 then conducted an open-label trial that
randomized 370 patients with severe LN and an average
serum creatinine of 1.1mg/dl to receive prednisone plus
either MMF (average dose 2.6 gm/d) or NIH-protocol i.v.
CYC for 24 weeks as induction therapy. Although 64 (17%)
patients were withdrawn during the trial (the majority for
adverse events), the response to treatment at the end of
induction therapy was similar in the MMF and i.v. CYC
groups, with 56% and 53% of patients responding to
treatment, respectively. The percentage of patients who
experienced adverse events was similar between treatment
groups. These trials validated the use of MMF as a safe
and effective induction therapy for severe LN compared with
i.v. CYC.
A subgroup analysis of the two largest randomized trials
comparing MMF with i.v. CYC concluded that MMF was also
equivalent specifically in class V LN,11 with a trend toward
higher rates of lymphopenia and leucopenia in the i.v. CYC
group but no difference in rates of infection. The efficacy of
MMF as induction therapy in class V LN has also been
supported by a small, non-randomized prospective study as
first-line therapy,12 as well as second-line therapy in a
retrospective case series.13 Moreover, a randomized trial
demonstrated that steroids plus MMF or oral CYC followed
by azathioprine led to equivalent outcomes at 1 year of
follow-up in patients with class IV LN.14
Small retrospective studies have shown that MMF may be
a useful therapy in aggressive forms of LN and extrarenal
lupus as well. In crescentic LN, a small randomized trial
demonstrated that MMF was equivalent to CYC in inducing
remission of disease at 12 months of follow-up, but MMF
achieved a higher rate of complete remission (54% vs. 27%)
over this time period.15 It is noteworthy that B25% of
patients in each group had serum creatinine levels43.0mg/dl,
indicating that MMF is a useful therapy in patients with
compromised renal function as well. A small, prospective
randomized trial indicated that MMF was superior to i.v.
CYC for class IV LN with necrotizing vasculopathy.16 Finally,
MMF was as effective as i.v. CYC in preventing non-renal
manifestations of lupus in patients who were treated for LN17
and was associated with better quality of life than oral CYC
induction therapy (followed by azathioprine maintenance
therapy) in patients who had received both treatments for
different LN flare episodes.18 Taken together, these studies
suggest that MMF is equivalent or superior to i.v. CYC as
induction therapy for many subtypes of severe LN, in
patients with increased serum creatinine levels, and likely has
a more favorable side-effect profile.
Whereas many earlier studies used i.v. CYC and/or
glucocorticoids as maintenance treatment, in the past 8 years
randomized trials have established MMF as maintenance
therapy for LN. Contreras et al.19 used NIH-regimen i.v. CYC
Table 1 | Trials comparing CYC and MMF during induction therapy of lupus nephritisa
Medication dosage
Complete
remission
Partial
remission Adverse reactions
Study Study type MMF dose CYC dose
Patients
(MMF/CYC) MMF CYC MMF CYC Total Deaths Infections GI Blood
Hu Single NRCT 0.5–0.75 g Q12H 0.75–1 g/m2 23/23 8 5 8 11 10/19 0/0 4/7 6/10 0/2
Duncan Single NRCT 1 g Q12H 0.5 g/m2 10/20 10 20
Chan Single open RCT 1 g Q12H 2.5 g/kg 33/31 24 23 8 7 9/46 0/2 4/12 3/1 0/8
Ginzler Multicenter
open RCT
1 g Q8H 71/69 16 4 21 17 83/75 9/5 19/17 77/91 23/12
Ong Single open RCT 1 g Q12H 0.75–1 g/m2 19/25 5 3 6 10 1/1 6/6 7/13
Flores-Suarez Single open
RCT
NR NR 10/10 3 1 3 1 0/3 5/3 2/0 1/5
Choi 2 g/day 0.75–1 g/m2 19/26 8 12 7 8
Wang Single open RCT 0.75–1 g Q12H 0.75–1 g/m2 9/11 4 0 2 3 0/0 1/12 0/5 0/2
Tang Retrospective
controlled study
0.75–1 g Q12H 0.5–0.75 g/m2 27/25 14 6 5 10 2/5 1/3 0/2 1/0
Traitanon Single NRCT 1440mg/db 0.5–1 g/m2 16/15 1 2 4 7 1/6 6/12 3/15
Appel Multicenter
open RCT
2.6 g/day 0.75 g/m2 135/156 16 15 89 86 177/171 9/5 19/17 77/91 23/12
Abbreviations: CYC, cyclphosphamide; GI, gastrointestinal; MMF, mycophenolate mofetil; NR, not recorded; NRCT, non-randomized controlled trial; RCT, randomized
controlled trial.
Data are from reference 25, which is a meta-analysis of the geographical variation in the response of lupus nephritis to MMF and CYC.
aAdapted from Mohan and Radhakrishnan.25
bEnteric coated mycophenolic acid used.
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as induction therapy, then compared quarterly i.v. CYC,
MMF, and azathioprine (all in combination with prednisone)
as maintenance therapy. This study demonstrated that MMF
and azathioprine were superior to i.v. CYC in preventing the
combined end point of patient death and chronic renal
failure at 6 years after induction with i.v. CYC. Moreover, the
MMF group had the lowest relapse rate and was associated
with a lower incidence of adverse events (primary amenor-
rhea and infections) than i.v. CYC. Recently, two randomized
trials demonstrated that MMF is equivalent20 or superior21 to
azathioprine as maintenance therapy for LN after 3 years of
follow-up. It is noteworthy that the patients in the ALMS
Maintenance Trial who were treated with MMF as main-
tenance therapy after induction treatment with i.v. CYC had
less treatment failure events than those treated with MMF as
induction therapy, although this difference was not signifi-
cant. These trials have demonstrated that MMF is superior to
quarterly i.v. CYC, and equivalent or superior to daily oral
azathioprine as maintenance treatment for LN.
Racial/ethnic and socioeconomic differences have been
observed in the serologic and histologic presentation of
LN.22,23 This has generated the hypothesis that the mechan-
ism of LN may differ between patients of different races, and
that the efficacy of different treatments may also vary between
racial groups. Most of the randomized trials that compared
i.v. CYC with MMF for LN are single-center studies, and
many do not specify the races or ethnicities of the enrolled
patients. The ALMS trial is the largest trial for induction
therapy for LN with i.v. CYC versus MMF. It was an
international, multicenter trial that also collected ethnic and
racial data. It was observed that Black and Hispanic patients
had higher response rates to MMF compared with i.v. CYC,
whereas the two induction therapies were equivalent in the
other racial groups.24 A recent meta-analysis confirmed this
observation using the location of each trial as a geographical
surrogate for the racial background of patients.25 It has also
been noted that studies conducted in Asia have higher
response rates to treatment than those conducted outside of
Asia. At this time, the available data suggest that MMF may be
more effective than i.v. CYC in Black and Hispanic patients,
but the two treatments are equivalent in other racial groups.
There is additional interest in the use of MMF in children
with severe LN given the gonadal toxicity associated with
CYC. In children with severe LN, there are no prospective,
randomized trials that have compared CYC with MMF; all
studies have been small and retrospective. The available data
suggest that MMF may be an effective maintenance therapy
for severe LN, but that i.v. CYC is still the mainstay of
induction treatment. It is interesting to note that the largest
retrospective analysis of children with LN, which separated
patients by era of treatment, showed that renal survival
improved significantly with the addition of MMF in the early
1990s, whereas this effect was not observed with the addition
of i.v. CYC.2 Although MMF seems to be a safe and effective
maintenance therapy in children, prospective studies are
required to establish its use as induction therapy.
CYC versus MMF: pharmacology, adverse events, and cost
CYC is a prodrug that is metabolized to active (phosphoramide
mustard) and toxic (acrolein) metabolites. Phosphoramide
mustard is an alkylating agent that cross-links DNA strands to
prevent cell division and cause cell death, including loss of
ovarian follicles and spermatocytes. Acrolein is believed to be
the cause of both cystitis and bladder cancer. Both of these
metabolites are derived from hepatic metabolism of CYC to the
initial metabolite 4-hydroxycyclophosphamide, which is sub-
sequently converted to aldophosphamide. Aldophosphamide
in the plasma is then converted to the active and toxic
metabolites.
MMF and MMF sodium are prodrugs that are quickly
hydrolyzed to the active moiety, mycophenolic acid. Myco-
phenolic acid is a selective, noncompetitive, reversible inhibitor
of inosine monophosphate dehydrogenase, a component of the
de novo pathway for guanine nucleotide synthesis. B and T
lymphocytes depend on this pathway for cell proliferation,
whereas other cell types are able to use alternative pathways.
Mycophenolic acid thus reversibly inhibits lymphocyte func-
tion and proliferation, including antibody production.
With the availability of these less toxic regimens, the
following question is raised: is it time to ‘retire’ CYC from the
LN armamentarium?
As CYC and MMF are shown to be equivalent as induction
therapies for the treatment of LN, it is important to consider
the respective severity and relative frequency of their acute/
subacute and chronic toxicities. With respect to the induction
treatment of LN, a number of systematic reviews and meta-
analyses have been performed. One of the earliest of these
analyses included four studies with a total of 268 patients,
which found that leukopenia and amenorrhea were more
common with CYC than with MMF treatment.26 Similarly,
another analysis of three studies (206 patients) found a
statistically lower incidence of leukopenia in the MMF
treatment group.27 Significant reductions in the incidence of
alopecia, as well as amenorrhea, were seen in the MMF-
treated arms of four trials (618 patients) in an analysis by
Touma et al.28 (Table 2). In a meta-analysis and meta-
regression comparing CYC and MMF in 10 studies (847
patients as induction and/or maintenance therapy for LN),
there was a significantly lower risk of developing amenorrhea
and leukopenia with MMF.29
As LN is most commonly seen in premenopausal women,
some adverse effects of CYC (alopecia and amenorrhea) are
especially troubling in this patient group. Whereas short- or
long-term therapy with MMF (for LN or in transplantation,
respectively) is not associated with ovarian failure, short-
course (6 months) or long-course (2 years) intermittent
monthly/quarterly pulse CYC therapy is associated with a
cumulative dose/duration-dependent amenorrhea (incidence
reported to be 23–56%), which may be permanent.30–32 Even if
amenorrhea does not occur with CYC, premature menopause
may occur years after treatment.31 Leuprolide acetate or
goserelin have been advocated as an additional drug therapies
to prevent ovarian failure in women, and testosterone to
1258 Kidney International (2012) 82, 1256–1260
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prevent azoospermia in men; however, this issue has not been
studied in randomized controlled trials.
The use of CYC is also associated with a risk of developing
hemorrhagic cystitis and/or transitional cell carcinoma of the
bladder. Although the incidence of these complications seems
to be very low with intermittent pulse CYC regimens used for
LN, MMF has not been associated with either of them in any
of the controlled trials using this agent.
Though not in widespread use in the United States, oral
CYC is commonly used to treat severe LN in other countries. In
two randomized studies comparing oral CYC (2.5mg/kg/day
for 6 months) with MMF, there was no difference in clinical
response, but adverse events were higher in the CYC group.14,33
Conversely, in an observational study, using lower doses of oral
CYC (1.0–1.5mg/kg/day for 2–4 months), response rates and
adverse events were comparable to historical controls.34
Another consideration is the cost/convenience of CYC
therapy for glomerulonephritis. Although the price of a course
of intravenous pulse CYC injections when calculated by the
number of drug vials required may be less expensive than
the cost of a course of oral MMF therapy when calculated by
the number of tablets required, other expenses such as the cost
of the supplies required to prepare an intravenous CYC dose,
the personnel who prepare and administer the treatment, and
the clinic or office/hospital space where the treatment occurs
are all costs that need to be factored into the final cost
equation. In addition, if the prevention of hemorrhagic cystitis
and monitoring for bladder cancer is desired, factors such as
pre/post-hydration, administration of mesna, urine cytology,
and cystoscopy/biopsy should be added to the cost estimate.
Anti-emetic agents, either prophylactically or treatment
emergent would pertain to CYC therapy, whereas with MMF
any gastrointestinal side effects, including nausea/vomiting and
especially diarrheas, would be managed by a simple dose
reduction. A cost-effectiveness study from the United Kingdom
comparing MMF with CYC (which considered most of the
above-mentioned factors) in the treatment of LN concluded
that MMF was less expensive than CYC, and in fact
demonstrated that MMF cost about half of what CYC would
cost for a 24-week course of induction therapy (Table 3).35 The
requirement for an office/clinic visit to administer CYC was the
major factor in determining the cost difference. In addition,
treatment with MMF resulted in a superior quality of life and
quality-adjusted life years.
An additional pharmacoeconomic study conducted in
Hong Kong concluded that therapy with CYC was less
expensive than with MMF; however, oral CYC was used and a
2-year treatment course was examined.36 Thus, the associated
costs of intravenous CYC were not considered, including
ancillary drugs for the prevention/treatment of possible side
effects (see above). As it included the cost of MMF during
maintenance (18 months of treatment), its relevance is
diminished (azathioprine, not CYC, was used). Interestingly,
the number of days of hospitalization in the CYC group was
nearly sixfold greater than in the MMF group, although this
did not reach statistical significance (P¼ 0.055) presumably
because of a small sample size (n¼ 44).
Final economic issues not yet resolved include the cost
differential of MMF versus CYC in resource-limited settings,
and the availability of generic MMF.
MMF as preferred treatment for LN
Given the efficacy, favorable side-effect profile, and perhaps
cost equivalence of MMF, why then is CYC still in use? There
are several explanations that can be forwarded to account for
this behavior. First, a change in practice after introduction of
new therapies or technologies is usually gradual. Second, the
long-term follow-up data for patients treated with MMF are
shorter compared with CYC: the Contreras and ALMS
maintenance trials reported on 6 and 3 years of follow-up,
respectively, compared with up to 200 months with oral
CYC1 and 160–220 months for i.v. CYC.3,4 Third, the data on
the efficacy of CYC versus MMF on the severest forms of LN
(e.g., associated with crescentic necrotic lesions/rapidly
progressive glomerulonephritis) are limited. Fourth, the
recent analysis of MMF versus azathioprine in the ALMS
maintenance trial demonstrated that within the group that
received MMF as maintenance therapy there was a non-
significant trend toward increased treatment failure in those
who had received MMF versus CYC as induction therapy.21
Finally, evidence supports geographical and racial differences
in response rates to induction treatment with MMF versus
Table 3 | Cost comparison for LN induction therapy using CYC
or MMFa
Mean cost of 6 months
of LN induction therapy English pounds US dollars
MMF d1388 $2138
CYC d2994 $4611
MMF–CYC d1606 $2473
Abbreviations: CYC, cyclphosphamide; LN, lupus nephritis; MMF, mycophenolate
mofetil.
Cost data from are from 2005, according to the UK National Health Service.
d1=$1.54.
Includes actual drug costs, nursing costs, blood tests, cost to treat infections, clinic
visits, and for CYC the costs of ondansetron, goserelin, mesna, and hydration.
Does not include costs common to both treatments, e.g., corticosteroid therapy.
MMF–CYC=difference in cost between MMF and CYC regimens.
aData are from ref. 35.
Table 2 | Comparison of side effects of CYC and MMF during
induction therapy of LNa
CYC (%), n MMF (%), n
Leukopenia 21 (243) 11 (235)
Infections 49.7 (310) 46.7 (=308)
Gastrointestinal 72.2 (310) 56.2 (=308)
Herpes zoster 7.7 (310) 10.1 (=308)
Amenorrhea 6.4 (310) 0.006 (=308)
Alopecia 28.4 (=285) 6.9 (=289)
Abbreviations: CYC, cyclphosphamide; LN, lupus nephritis; MMF, mycophenolate
mofetil.
All patients received concomitant corticosteroid therapy.
n=number of patients in each arm.
aData are from Touma et al.28, which examined four trials comparing CYC versus
MMF for induction therapy of LN.
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CYC for LN.24,25,37 Physicians may hesitate in shifting their
therapeutic strategy for the treatment of LN owing to these
reasons. Subsequently, many nephrologists switch from MMF
to CYC when there is a lack of a satisfactory response to the
former drug (personal observation), despite a lack of reports
to support this practice.
To summarize, in the authors’ opinion, MMF should now
be considered standard first-line therapy for severe LN given
the favorable efficacy/toxicity profile over i.v. CYC, especially
in women of childbearing age and non-Asian patients.
Moreover, MMF has been shown to be a superior main-
tenance therapy to both azathioprine and i.v. CYC. However,
i.v. CYC given as a 6-monthly course, the attenuated ELNT
regimen, or oral CYC are quite reasonable when compliance
is an issue, in developing countries where the cost of MMF is
still high, in children, and perhaps in patients with the
severest form (Rapidly progressive glomerulonephritis/cres-
centic) of LN. Long-term studies in these populations,
further exploration of differences in treatment response
because of geography and race, and the availability of generic
MMF would solidify its role as the preferred first-line therapy
for induction and maintenance treatment in severe LN.
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